US3980650A
(en)
*
|
1972-05-05 |
1976-09-14 |
N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia |
4-Amino-pyrimidine derivatives
|
GB1383409A
(en)
*
|
1972-09-09 |
1974-02-12 |
Pfizer Ltd |
Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
|
JPS4966691A
(fr)
*
|
1972-10-30 |
1974-06-27 |
|
|
US4026894A
(en)
*
|
1975-10-14 |
1977-05-31 |
Abbott Laboratories |
Antihypertensive agents
|
US4060615A
(en)
*
|
1976-02-18 |
1977-11-29 |
Mead Johnson & Company |
2-Piperazinyl-6,7-dimethoxyquinazolines
|
DK140695C
(da)
|
1976-05-07 |
1980-05-12 |
Synthelabo |
Analogifremgangsmaade til fremstilling af 2,4-diamino-6,7-dimethoxyquinazolinderivater eller syreadditionssalte heraf
|
SE435380B
(sv)
|
1976-06-15 |
1984-09-24 |
Pfizer |
Forfarande for framstellning av kinazolinforeningar
|
US4171363A
(en)
*
|
1977-02-22 |
1979-10-16 |
Bristol-Myers Company |
1,2,3-Thiadiazole process
|
US4101548A
(en)
*
|
1977-02-22 |
1978-07-18 |
Bristol-Myers Company |
1,2,3-Thiadiazole amides
|
US4102885A
(en)
*
|
1977-06-20 |
1978-07-25 |
Bristol-Myers Company |
Process for preparing 2,4-dihaloquinazolines
|
US4098788A
(en)
*
|
1977-06-20 |
1978-07-04 |
Bristol-Myers Company |
Process for preparing quinazolines
|
US4130647A
(en)
*
|
1977-07-08 |
1978-12-19 |
Pfizer Inc. |
Methods for treating congestive heart failure and ischemic heart disease
|
DK154082C
(da)
*
|
1977-11-05 |
1989-02-27 |
Pfizer |
Analogifremgangsmaade til fremstilling af 4-amino-6,7-dimethoxy-2-(piperazin-1-yl eller homopiperazin-1-yl)-quinazolinforbindelser eller farmaceutisk acceptable syreadditionssalte deraf
|
US4188390A
(en)
*
|
1977-11-05 |
1980-02-12 |
Pfizer Inc. |
Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
|
US4287341A
(en)
*
|
1979-11-01 |
1981-09-01 |
Pfizer Inc. |
Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
|
US4377581A
(en)
*
|
1980-03-03 |
1983-03-22 |
Pfizer Inc. |
Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
|
US4351940A
(en)
*
|
1980-03-03 |
1982-09-28 |
Pfizer Inc. |
Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
|
US4510307A
(en)
*
|
1980-08-20 |
1985-04-09 |
Asahi Kasei Kogyo Kabushiki Kaisha |
6-Quinazolinesulfonyl derivatives and process for preparation thereof
|
FI70411C
(fi)
|
1980-12-29 |
1986-09-19 |
Pfizer |
Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
|
US4704284A
(en)
*
|
1982-08-12 |
1987-11-03 |
Pfizer Inc. |
Long-acting matrix tablet formulations
|
US4582832A
(en)
*
|
1984-10-09 |
1986-04-15 |
Pfizer Inc. |
Trimazosin as an anti-atherosclerosis agent
|
GB8910722D0
(en)
*
|
1989-05-10 |
1989-06-28 |
Smithkline Beckman Intercredit |
Compounds
|
PT100905A
(pt)
*
|
1991-09-30 |
1994-02-28 |
Eisai Co Ltd |
Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
|
DE69406945T2
(de)
*
|
1993-10-18 |
1998-03-12 |
Ici Plc |
Katalytisches verfahren
|
AU2001293817A1
(en)
*
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
CN1681495B
(zh)
|
2002-08-19 |
2010-05-12 |
辉瑞产品公司 |
用于治疗过度增生性疾病的组合物
|
US7759336B2
(en)
*
|
2002-12-10 |
2010-07-20 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
CA2526730A1
(fr)
*
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Derives pyrroliques substitues
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
CN101031551A
(zh)
*
|
2004-07-06 |
2007-09-05 |
安吉永生物制药公司 |
针对癌症治疗的肝细胞生长因子/c-met活性的喹唑啉调节剂
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
SG166829A1
(en)
*
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US20070213319A1
(en)
*
|
2006-01-11 |
2007-09-13 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c-Met activity
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
AR059838A1
(es)
*
|
2006-03-14 |
2008-04-30 |
Ranbaxy Lab Ltd |
Formulaciones para dosis estabilizantes de estatina
|
BRPI0714361A2
(pt)
*
|
2006-07-14 |
2013-03-26 |
Ranbaxy Lab Ltd |
polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento
|
ES2382009T3
(es)
|
2006-12-01 |
2012-06-04 |
Bristol-Myers Squibb Company |
Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
|
JP2016516804A
(ja)
|
2013-04-17 |
2016-06-09 |
ファイザー・インク |
心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体
|
WO2016055901A1
(fr)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Composés d'amide substitué
|
EP3911648A4
(fr)
|
2019-01-18 |
2022-10-26 |
Astrazeneca AB |
Inhibiteurs de pcsk9 et leurs procédés d'utilisation
|